RELIEF THERAPEUTICS Secures Financial Flexibility with Renewed CHF 50 Million SSF Agreement with GEM
Summary
RELIEF THERAPEUTICS Holding SA, a pioneering biopharmaceutical firm, has solidified its financial strategy by renewing a critical Share Subscription Facility (SSF) agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited, ensuring continued support for its innovative healthcare solutions. This renewed partnership, extending for an additional three years, empowers Relief with the ability to issue shares worth up to CHF 50 million, providing a substantial boost to its development initiatives.Since 2016, GEM, the largest shareholder of Relief, has demonstrated unwavering support for the companys mission to address unmet and rare diseases. The renewal of the SSF agreement not only reaffirms GEMs commitment but also provides Relief with enhanced financial flexibility. Moreover, GEM is set to receive warrants to purchase up to 3.35 million ordinary Relief shares at CHF 1.70 each, exercisable until January 2027. As the company looks forward to the shareholder meeting, the healthcare community watches closely, anticipating the impact this financial maneuver will have on Reliefs ability to bring innovative treatments to market.